drugset
drugset / Trial / NCT05084911

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)

NCT05084911 ↗

Phase 3 Completed 1807 enrolled Shin Poong Pharmaceutical Co. Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase III clinical trial to evaluate efficacy and safety of pyramax in mild to moderate COVID-19 patients.

Timeline

Start
2021-10-18
Primary completion
2023-03-24
Completion
2023-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule 60 mg —
Subject Pyronaridine Unknown 180 mg —

Indications

COVID-19